P
Philip J. Rosenfeld
Researcher at University of Miami
Publications - 358
Citations - 32577
Philip J. Rosenfeld is an academic researcher from University of Miami. The author has contributed to research in topics: Macular degeneration & Optical coherence tomography. The author has an hindex of 77, co-authored 325 publications receiving 28506 citations. Previous affiliations of Philip J. Rosenfeld include Massachusetts Eye and Ear Infirmary & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
Mohammad Azab,Mustapha Benchaboune,Kevin J. Blinder,Neil M. Bressler,Susan B. Bressler,Evangelos S. Gragoudas,Gary E. Fish,Yong Hao,Laurie Haynes,Jennifer I. Lim,Ugo Menchini,Joan W. Miller,Jordi Monés,Michael J. Potter,Reaves A,Philip J. Rosenfeld,H. Andrew Strong,Xiang Yao Su,Jason S. Slakter,Ursula Schmidt-Erfurth,John A. Sorenson +20 more
TL;DR: In 948 ARMD patients, verteporfin therapy had an overall safety profile similar to that for placebo, with a few exceptions, and visual disturbances did not affect the net vision outcome benefits associated with treatment that has been reported previously.
Journal ArticleDOI
Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy.
Gary Shienbaum,Carlos Alexandre de Amorim Garcia Filho,Harry W. Flynn,Renata Portella Nunes,William E. Smiddy,Philip J. Rosenfeld +5 more
TL;DR: Management with anti-VEGF monotherapy may yield visual and anatomic improvements in eyes with marked submacular hemorrhage secondary to neovascular AMD.
Journal ArticleDOI
One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion.
Ninel Z. Gregori,Philip J. Rosenfeld,Carmen A. Puliafito,Harry W. Flynn,Ji Eun Lee,Elias C. Mavrofrides,William E. Smiddy,Timothy G. Murray,Audina M. Berrocal,Ingrid U. Scott,Giovanni Gregori +10 more
TL;DR: IVTA can substantially improve vision in some patients, but most patients have stable visual acuity compared with baseline at 1 year despite repeated injections.
Journal ArticleDOI
Promising new treatments for neovascular age-related macular degeneration
TL;DR: For the first time in neovascular AMD, anti-VEGF drugs have brought the hope of vision improvement to a significant proportion of patients and many of these drugs have been adopted from oncology where antiangiogenic therapy is gaining wide acceptance.
Journal ArticleDOI
Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab
TL;DR: Eyes must be monitored closely after initial injection of intravitreal bevacizumab, regardless of intial angle status, as many may still require surgery to lower IOP or repeat injections of intraocular pressure-lowering medications.